212 related articles for article (PubMed ID: 32163418)
21. Dipeptidyl nitrile derivatives suppress the Trypanosoma cruzi in vitro infection.
Quilles JC; Shamim A; Tezuka DY; Batista PHJ; Lopes CD; de Albuquerque S; Montanari CA; Leitão A
Exp Parasitol; 2020 Dec; 219():108032. PubMed ID: 33137308
[TBL] [Abstract][Full Text] [Related]
22. S1 subsite specificity of a recombinant cysteine proteinase, CPB, of Leishmania mexicana compared with cruzain, human cathepsin L and papain using substrates containing non-natural basic amino acids.
Alves LC; Melo RL; Sanderson SJ; Mottram JC; Coombs GH; Caliendo G; Santagada V; Juliano L; Juliano MA
Eur J Biochem; 2001 Mar; 268(5):1206-12. PubMed ID: 11231271
[TBL] [Abstract][Full Text] [Related]
23. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Mott BT; Ferreira RS; Simeonov A; Jadhav A; Ang KK; Leister W; Shen M; Silveira JT; Doyle PS; Arkin MR; McKerrow JH; Inglese J; Austin CP; Thomas CJ; Shoichet BK; Maloney DJ
J Med Chem; 2010 Jan; 53(1):52-60. PubMed ID: 19908842
[TBL] [Abstract][Full Text] [Related]
24. Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases.
Silva LR; Guimarães AS; do Nascimento J; do Santos Nascimento IJ; da Silva EB; McKerrow JH; Cardoso SH; da Silva-Júnior EF
Bioorg Med Chem; 2021 Jul; 41():116213. PubMed ID: 33992862
[TBL] [Abstract][Full Text] [Related]
25. Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
Pereira GAN; da Silva EB; Braga SFP; Leite PG; Martins LC; Vieira RP; Soh WT; Villela FS; Costa FMR; Ray D; de Andrade SF; Brandstetter H; Oliveira RB; Caffrey CR; Machado FS; Ferreira RS
Eur J Med Chem; 2019 Oct; 179():765-778. PubMed ID: 31284086
[TBL] [Abstract][Full Text] [Related]
26. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
Roush WR; Cheng J; Knapp-Reed B; Alvarez-Hernandez A; McKerrow JH; Hansell E; Engel JC
Bioorg Med Chem Lett; 2001 Oct; 11(20):2759-62. PubMed ID: 11591518
[TBL] [Abstract][Full Text] [Related]
27. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Nicoll-Griffith DA
Expert Opin Drug Discov; 2012 Apr; 7(4):353-66. PubMed ID: 22458506
[TBL] [Abstract][Full Text] [Related]
28. Targeting Cysteine Proteases and their Inhibitors to Combat Trypanosomiasis.
Saha A; Pushpa ; Moitra S; Basak D; Brahma S; Mondal D; Molla SH; Samadder A; Nandi S
Curr Med Chem; 2024; 31(16):2135-2169. PubMed ID: 37340748
[TBL] [Abstract][Full Text] [Related]
29. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
30. Benzimidazole inhibitors of the major cysteine protease of
Pereira GA; Santos LH; Wang SC; Martins LC; Villela FS; Liao W; Dessoy MA; Dias LC; Andricopulo AD; Costa MA; Nagem RA; Caffrey CR; Liedl KR; Caffarena ER; Ferreira RS
Future Med Chem; 2019 Jul; 11(13):1537-1551. PubMed ID: 31469332
[No Abstract] [Full Text] [Related]
31. Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
Silva-Júnior EF; Silva EPS; França PHB; Silva JPN; Barreto EO; Silva EB; Ferreira RS; Gatto CC; Moreira DRM; Siqueira-Neto JL; Mendonça-Júnior FJB; Lima MCA; Bortoluzzi JH; Scotti MT; Scotti L; Meneghetti MR; Aquino TM; Araújo-Júnior JX
Bioorg Med Chem; 2016 Sep; 24(18):4228-4240. PubMed ID: 27475533
[TBL] [Abstract][Full Text] [Related]
32. Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and
Boudreau PD; Miller BW; McCall LI; Almaliti J; Reher R; Hirata K; Le T; Siqueira-Neto JL; Hook V; Gerwick WH
J Med Chem; 2019 Oct; 62(20):9026-9044. PubMed ID: 31539239
[TBL] [Abstract][Full Text] [Related]
33. Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Massai L; Messori L; Micale N; Schirmeister T; Maes L; Fregona D; Cinellu MA; Gabbiani C
Biometals; 2017 Apr; 30(2):313-320. PubMed ID: 28283781
[TBL] [Abstract][Full Text] [Related]
34. Structure-Based Virtual Screening and In Vitro Evaluation of New
Herrera-Mayorga V; Lara-Ramírez EE; Chacón-Vargas KF; Aguirre-Alvarado C; Rodríguez-Páez L; Alcántara-Farfán V; Cordero-Martínez J; Nogueda-Torres B; Reyes-Espinosa F; Bocanegra-García V; Rivera G
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30970549
[TBL] [Abstract][Full Text] [Related]
35. Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors.
Sartori GR; Leitão A; Montanari CA; Laughton CA
PLoS One; 2019; 14(12):e0222055. PubMed ID: 31856175
[TBL] [Abstract][Full Text] [Related]
36. 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
Giroud M; Kuhn B; Saint-Auret S; Kuratli C; Martin RE; Schuler F; Diederich F; Kaiser M; Brun R; Schirmeister T; Haap W
J Med Chem; 2018 Apr; 61(8):3370-3388. PubMed ID: 29590751
[TBL] [Abstract][Full Text] [Related]
37. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases.
Yong V; Schmitz V; Vannier-Santos MA; de Lima AP; Lalmanach G; Juliano L; Gauthier F; Scharfstein J
Mol Biochem Parasitol; 2000 Jun; 109(1):47-59. PubMed ID: 10924756
[TBL] [Abstract][Full Text] [Related]
38. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J
Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512
[TBL] [Abstract][Full Text] [Related]
39. Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.
Lee GM; Balouch E; Goetz DH; Lazic A; McKerrow JH; Craik CS
Biochemistry; 2012 Dec; 51(50):10087-98. PubMed ID: 23181936
[TBL] [Abstract][Full Text] [Related]
40. Metal compounds for the treatment of parasitic diseases.
Fricker SP; Mosi RM; Cameron BR; Baird I; Zhu Y; Anastassov V; Cox J; Doyle PS; Hansell E; Lau G; Langille J; Olsen M; Qin L; Skerlj R; Wong RS; Santucci Z; McKerrow JH
J Inorg Biochem; 2008 Oct; 102(10):1839-45. PubMed ID: 18684510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
